BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21992004)

  • 1. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
    Kwiatkowski N; Deng X; Wang J; Tan L; Villa F; Santaguida S; Huang HC; Mitchison T; Musacchio A; Gray N
    ACS Chem Biol; 2012 Jan; 7(1):185-96. PubMed ID: 21992004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
    Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
    Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
    Kaestner P; Stolz A; Bastians H
    Mol Cancer Ther; 2009 Jul; 8(7):2046-56. PubMed ID: 19584233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
    Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
    Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.
    Sloane DA; Trikic MZ; Chu ML; Lamers MB; Mason CS; Mueller I; Savory WJ; Williams DH; Eyers PA
    ACS Chem Biol; 2010 Jun; 5(6):563-76. PubMed ID: 20426425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.
    Heron NM; Anderson M; Blowers DP; Breed J; Eden JM; Green S; Hill GB; Johnson T; Jung FH; McMiken HH; Mortlock AA; Pannifer AD; Pauptit RA; Pink J; Roberts NJ; Rowsell S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1320-3. PubMed ID: 16337122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of aurora-A but not aurora-B impairs interphase microtubule dynamics.
    Lorenzo C; Liao Q; Hardwicke MA; Ducommun B
    Cell Cycle; 2009 Jun; 8(11):1733-7. PubMed ID: 19395863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel cell-based, high-content assay for phosphorylation of Lats2 by Aurora A.
    Emery A; Sorrell DA; Lawrence S; Easthope E; Stockdale M; Jones DO; Zheleva D; Scaerou F; Glover DM
    J Biomol Screen; 2011 Sep; 16(8):925-31. PubMed ID: 21788394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.
    Tyler RK; Shpiro N; Marquez R; Eyers PA
    Cell Cycle; 2007 Nov; 6(22):2846-54. PubMed ID: 18032922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.
    Nair JS; Ho AL; Tse AN; Coward J; Cheema H; Ambrosini G; Keen N; Schwartz GK
    Mol Biol Cell; 2009 Apr; 20(8):2218-28. PubMed ID: 19225156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of selective aminothiazole aurora kinase inhibitors.
    Andersen CB; Wan Y; Chang JW; Riggs B; Lee C; Liu Y; Sessa F; Villa F; Kwiatkowski N; Suzuki M; Nallan L; Heald R; Musacchio A; Gray NS
    ACS Chem Biol; 2008 Mar; 3(3):180-92. PubMed ID: 18307303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
    Tomita M; Tanaka Y; Mori N
    Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.
    Lawrence HR; Martin MP; Luo Y; Pireddu R; Yang H; Gevariya H; Ozcan S; Zhu JY; Kendig R; Rodriguez M; Elias R; Cheng JQ; Sebti SM; Schonbrunn E; Lawrence NJ
    J Med Chem; 2012 Sep; 55(17):7392-7416. PubMed ID: 22803810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
    Tao Y; Leteur C; Calderaro J; Girdler F; Zhang P; Frascogna V; Varna M; Opolon P; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Cell Cycle; 2009 Oct; 8(19):3172-81. PubMed ID: 19755861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors.
    Ando R; Ikegami H; Sakiyama M; Ooike S; Hayashi M; Fujino Y; Abe D; Nakamura H; Mishina T; Kato H; Iwase Y; Tomozane H; Morioka M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4709-11. PubMed ID: 20573509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
    Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S
    J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
    Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
    PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
    Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
    J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.